Business Description
DaShenLin Pharmaceutical Group Co Ltd
ISIN : CNE100002RG2
Compare
Compare
Traded in other countries / regions
603233.China IPO Date
2017-07-31Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.75 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 0.88 | |||||
| Debt-to-EBITDA | 3.58 | |||||
| Interest Coverage | 36.41 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.04 | |||||
| Beneish M-Score | -2.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 22.7 | |||||
| 3-Year EBITDA Growth Rate | 34.5 | |||||
| 3-Year EPS without NRI Growth Rate | 12.6 | |||||
| 3-Year FCF Growth Rate | 29.8 | |||||
| 3-Year Book Growth Rate | 12.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.91 | |||||
| 9-Day RSI | 36.17 | |||||
| 14-Day RSI | 37.41 | |||||
| 6-1 Month Momentum % | -18.46 | |||||
| 12-1 Month Momentum % | 25.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | |||||
| Quick Ratio | 0.67 | |||||
| Cash Ratio | 0.47 | |||||
| Days Inventory | 95.95 | |||||
| Days Sales Outstanding | 15.46 | |||||
| Days Payable | 134.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.52 | |||||
| Dividend Payout Ratio | 0.45 | |||||
| 3-Year Dividend Growth Rate | 23.3 | |||||
| Forward Dividend Yield % | 1.52 | |||||
| 5-Year Yield-on-Cost % | 1.5 | |||||
| 3-Year Average Share Buyback Ratio | -0.6 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.11 | |||||
| Operating Margin % | 8.18 | |||||
| Net Margin % | 5.1 | |||||
| ROE % | 18.74 | |||||
| ROA % | 5.99 | |||||
| ROIC % | 12.03 | |||||
| ROC (Joel Greenblatt) % | 28.65 | |||||
| ROCE % | 15.08 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 27.16 | |||||
| PE Ratio without NRI | 26.94 | |||||
| Shiller PE Ratio | 44.77 | |||||
| Price-to-Owner-Earnings | 73.31 | |||||
| PEG Ratio | 0.88 | |||||
| PS Ratio | 1.41 | |||||
| PB Ratio | 4.62 | |||||
| Price-to-Tangible-Book | 9.02 | |||||
| Price-to-Free-Cash-Flow | 12.85 | |||||
| Price-to-Operating-Cash-Flow | 8.37 | |||||
| EV-to-EBIT | 19.59 | |||||
| EV-to-EBITDA | 19.59 | |||||
| EV-to-Revenue | 1.42 | |||||
| EV-to-FCF | 13.15 | |||||
| Price-to-Projected-FCF | 1.6 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.61 | |||||
| Price-to-Graham-Number | 3.29 | |||||
| Earnings Yield (Greenblatt) % | 5.11 | |||||
| Forward Rate of Return (Yacktman) % | 20.36 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
DaShenLin Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 22,518.103 | ||
| EPS (TTM) (Â¥) | 1.208 | ||
| Beta | 1.07 | ||
| Volatility % | 40.56 | ||
| 14-Day RSI | 37.41 | ||
| 14-Day ATR (Â¥) | 0.912739 | ||
| 20-Day SMA (Â¥) | 33.448 | ||
| 12-1 Month Momentum % | 25.39 | ||
| 52-Week Range (Â¥) | 26.416666 - 47.36 | ||
| Shares Outstanding (Mil) | 949.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DaShenLin Pharmaceutical Group Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
DaShenLin Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
DaShenLin Pharmaceutical Group Co Ltd Frequently Asked Questions
What is DaShenLin Pharmaceutical Group Co Ltd(SHSE:603233)'s stock price today?
The current price of SHSE:603233 is ¥32.55. The 52 week high of SHSE:603233 is ¥47.36 and 52 week low is ¥26.42.
When is next earnings date of DaShenLin Pharmaceutical Group Co Ltd(SHSE:603233)?
The next earnings date of DaShenLin Pharmaceutical Group Co Ltd(SHSE:603233) is .
Does DaShenLin Pharmaceutical Group Co Ltd(SHSE:603233) pay dividends? If so, how much?
The Dividend Yield %  of DaShenLin Pharmaceutical Group Co Ltd(SHSE:603233) is 1.52% (As of Today), Highest Dividend Payout Ratio of DaShenLin Pharmaceutical Group Co Ltd(SHSE:603233) was 0.66. The lowest was 0.35. And the median was 0.45. The  Forward Dividend Yield % of DaShenLin Pharmaceutical Group Co Ltd(SHSE:603233) is 1.52%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
